Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
03 May 2022 - 9:00PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
Dr. Neal Walker, President and CEO, and Walter Smith, Scientific
and Business Development Consultant, of Aclaris will participate in
a virtual fireside chat at the LifeSci Partners Immunology &
Inflammation Symposium on Wednesday, May 11, 2022 at 9:00 a.m. ET.
A webcast of the fireside chat may be accessed
through the “Events” page of the “Investors” section of Aclaris’
website, www.aclaristx.com. The webcast will be archived for at
least 30 days on the Aclaris website.
About Aclaris Therapeutics,
Inc.
Aclaris Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates to address the needs of patients with
immuno-inflammatory diseases who lack satisfactory treatment
options. The company has a multi-stage portfolio of drug candidates
powered by a robust R&D engine exploring protein kinase
regulation. For additional information, please visit
www.aclaristx.com.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024